Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings and welcome to the PureTech Health ...

And based on preliminary analysis, we continue to see strong durable data. Our oncology program, LYT-200, delivered strong clinical data from our Phase 1b trial in AML as well as positive results ...

PureTech Health impressed the market with its annual results for 2024, as the company maintained a strong cash position while hitting a number of key clinical and regulatory milestones during the year ...

Phase 1b data for LYT-200 in the treatments of acute myeloid leukemia and solid tumours, and FDA approval of PureTech-invented Cobenfy for schizophrenia. The company said it also saw "rapid growth ...

There are 1b trial data coming later this year for LYT-200 but apart from that, its only phase 3 initiations without results until late 2026-27. Seaport initiating Phase 2 trials for Anxiety ...

11:34 EDT PureTech Health (PRTC) plc – American Depositary Shares trading resumes Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...

11:29 EDT PureTech Health (PRTC) plc – American Depositary Shares trading halted, volatility trading pause Discover the latest stocks recommended by top Wall Street analysts, all in one place ...

8th Apr 2025 2:53 pm GNW Invesco Ltd: Form 8.3 - PureTech Health PLC; Opening Position disclosure 8th Apr 2025 2:48 pm EQS Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc 8th Apr 2025 1:15 pm ...